Daiichi Sankyo Company, Limited 4568

Daiichi Sankyo Company has seen its share price fall over the past few years, so the key issue now is whether the current market value lines up with the cash the business is expected to generate. With investors also weighing fresh data around its cancer portfolio, the question is how much of that potential is already reflected in the price you see today. Over the past 3 years the stock has declined 27.6%, which puts the focus squarely on whether the underlying cash flows still support...

Daiichi Sankyo Company (TSE:4568) is back in focus after it voluntarily withdrew a U.S. accelerated approval filing for ifinatamab deruxtecan, while larger Phase 3 trials for the drug continue across several cancer indications. The latest ifinatamab setback has followed a weaker run for Daiichi Sankyo Company, with the share price at ¥2,800 and the year-to-date share price return down 20.68%, while the 1-year total shareholder return has fallen 14.53% and the 5-year total shareholder return...

Daiichi Sankyo Co Ltd (DSKYF) recently announced a total dividend of $0.31 per share, with the ex-dividend date set for 2026-09-29. This amount consists entirely of a $0.31 per share cash dividend. As investors look forward to this upcoming payment, the spotlight also shines on the company's dividend history, yield, and growth rates.

Merck & Co., Inc. (NYSE:MRK) and Daiichi Sankyo announced on September 25 that they voluntarily withdrew the U.S. application for ifinatamab deruxtecan in adults whose extensive-stage small-cell lung cancer progressed during or after platinum-based chemotherapy. Following FDA discussions, the partners said the submitted evidence, including Phase 2 results, did not satisfy accelerated-approval requirements. The investment […]

It was reported on September 25 that the U.S. FDA has accepted and granted Priority Review to AstraZeneca PLC (NYSE:AZN)’s supplemental Biologics License Application (sBLA) for IMFINZI (durvalumab) in combination with enfortumab vedotin (EV). The regimen treats muscle-invasive bladder cancer (MIBC) in patients ineligible for or declining cisplatin-based chemotherapy. Supported by Phase III VOLGA trial […]

Key Stats for Merck StockCurrent Price: $148. 74Target Price (Mid): ~$166Street Target: ~$154Potential Total Return: ~12%Annualized IRR: ~3% / yearWhat Happened?Daiichi Sankyo and Merck (MRK) withdrew their application for accelerated U.

AZN's oncology sales rise 15% in H1 2026 as newer drugs, label expansions and a deep pipeline support continued franchise growth.

The FDA indicated that the data generated so far wouldn’t support an accelerated clearance of “I-DXd,” a setback that erases an edge Merck and Daiichi had over multiple fast-moving competitors.

TOKYO, September 25, 2026--The Biologics License Application (BLA) seeking accelerated approval in the U.S. for Daiichi Sankyo (TSE: 4568) and Merck’s (NYSE: MRK), known as MSD outside of the United States and Canada, ifinatamab deruxtecan (I-DXd) for the treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC) with disease progression on or after platinum-based chemotherapy has been voluntarily withdrawn.

AstraZeneca PLC (NYSE:AZN) announced on September 11, 2026, that its Phase III SERENA-4 trial evaluating Etcamah (camizestrant) in combination with palbociclib failed to meet its primary endpoint of progression-free survival (PFS) in patients with upfront first-line ER-positive, HER2-negative advanced breast cancer. While the regimen demonstrated numerical improvement over standard anastrozole plus palbociclib, it did not […]

TOKYO, September 18, 2026--Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2+ eBC

AstraZeneca (LSE:AZN) and Daiichi Sankyo reported DESTINY-Lung04 Phase III results showing ENHERTU delayed disease progression in HER2-mutant advanced NSCLC versus standard therapy. Long-term follow-up data for TAGRISSO indicated eight-year survival benefits in early-stage EGFR-mutated lung cancer patients already on treatment protocols. Tozorakimab emerged as the first biologic to show efficacy in reducing exacerbations across a broad chronic obstructive pulmonary disease population in...

NHS reimbursement expands patient access, but confidential pricing prevents a reliable revenue calculation.

The UK-Swedish pharma giant has shared readouts from key portfolio assets such as Enhertu, Tagrisso and Etcamah.

Daiichi Sankyo and AstraZeneca’s Enhertu, in combination with pertuzumab, was approved in the European Union in September 2026 for first-line treatment of unresectable or metastatic HER2 positive breast cancer, triggering a US$100 million milestone payment from AstraZeneca to Daiichi Sankyo. Separately, a court dismissed all claims brought by Northern TK Venture Pte Ltd against Daiichi Sankyo, removing a legal overhang while Enhertu’s expanded EU use underscores the company’s strengthening...

WILMINGTON, Del., September 14, 2026--Positive results from the DESTINY-Lung04 Phase III trial showed AstraZeneca and Daiichi Sankyo’s ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) versus global standard of care (platinum-pemetrexed doublet chemotherapy plus pembrolizumab) as a 1st-line treatment of patients with unresectable, locally advanced or metastatic HER2-mutant non-squamous non-

TOKYO, September 14, 2026--Enhertu Demonstrated a Median 14.3 Month Progression-Free Survival as First-Line Therapy in Patients with HER2 Mutant Advanced NSCLC in DESTINY-Lung04

By Karen Roman Veraxa Biotech AG (Nasdaq: VRXA) said it appointed Raju Willener as Chief Financial Officer, having previously served as Director of Corporate Development at Exentis Group AG, before becoming its CFO in 2025. Mr. Willener has more than three decades of international financial leadership experience in global capital markets and all aspects of […] The post VERAXA Biotech Designates Raju Willener as CFO appeared first on ExecEdge.